BiCNU (Carmustine) for Myeloma | MyMyelomaTeam

Connect with others who understand.

sign up Log in
About MyMyelomaTeam
Powered By

BiCNU is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating multiple myeloma and other cancers. BiCNU is often combined with other drugs such as corticosteroids. BiCNU is also known by its drug name, carmustine.

BiCNU is an anticancer drug used in chemotherapy. BiCNU is a member of a class of drugs called alkylating agents. BiCNU is believed to work by preventing the production of DNA in cells, thereby blocking cell division.

How do I take it?
BiCNU is administered as an intravenous infusion during chemotherapy treatment.

Side effects
The FDA-approved label for BiCNU lists common side effects including nausea, vomiting, kidney toxicity, lung disease and toxicity, and low blood count.

Rare but serious side effects listed for BiCNU include damage to skin, lungs, liver, or eyes, increased risk for other cancers, and fetal harm in pregnant women.

For more details about this treatment, visit:

BiCNU — RxList

Drug Therapy for Multiple Myeloma — American Cancer Society

Continue with Facebook
Continue with Google
Your privacy is our priority. By continuing, you accept our Terms of use and Privacy policy.
Already a Member? Log in